Although topical and systemic sirolimus is very efficacious for another mTOR-activating inherited genetic disorder, tuberous sclerosis23,24, sirolimus failed to reduce the neurofibroma volume in progressing and non-progressing neurofibromas21,22. This evidence concerns the gene MTOR and plexiform neurofibroma.